Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research

Estimating the Force of Infection for Dengue Virus Using Repeated Serosurveys, Ouagadougou, Burkina Faso

Jacqueline K. LimComments to Author , Mabel Carabali, Tansy Edwards, Ahmed Barro, Jung-Seok Lee, Desire Dahourou, Kang Sung Lee, Teguewende Nikiema, Mee Young Shin, Emmanuel Bonnet, Therese Kagone, Losseni Kaba, Suk Namkung, Paul-André Somé, Jae Seung Yang, Valéry Ridde, In-Kyu Yoon, Neal Alexander, and Yaro Seydou
Author affiliations: International Vaccine Institute, Seoul, South Korea (J.K. Lim, M. Carabali, J.-S. Lee, K.S. Lee, M.Y. Shin, S. Namkung, J.S. Yang); London School of Hygiene and Tropical Medicine, London, UK (J.K. Lim, T. Edwards, N. Alexander); Centre MURAZ, Bobo-Dioulasso, Burkina Faso (D. Dahourou, T. Nikiema, T. Kagone, Y. Seydou); McGill University, Montreal, Quebec, Canada (M. Carabali); Action, Gouvernance, Intégration, Renforcement Program Equité, Ouagadougou, Burkina Faso (A. Barro, P.-A. Somé); Institut de Recherché en Sciences de la Santé, Ouagadougou (D. Dahourou); I; nstitute for Research on Sustainable Development, Université de Paris, Paris, France (E. Bonnet, V. Ridde); Centre National de Transfusion Sanguine, Ouagadougou (L. Kaba); Coalition for Epidemic Preparedness Innovations, Washington, DC, USA (I.-K. Yoon)

Main Article

Table 3

Univariable binomial regression showing ratio of rates of seroconversion in study of force of infection for dengue virus, based on results of IgG indirect ELISA assays, Ouagadougou, Burkina Faso, June–July 2015*

Characteristics S1–S2,† N = 455, IgG-S (n = 33) vs. IgG-N (n = 422)
 S2–S3,† N = 443, IgG-S (n = 23) vs. IgG-N (n = 420)
 S3–S4,† N = 455, IgG-S (n = 78) vs. IgG-N (n = 377)
IgG-S rate (95% CI) p value‡ IgG-S rate (95% CI) p value‡ IgG-S rate (95% CI) p value‡
Age range, y 0.006 0.002 0.038
1–4 Referent
Referent§
Referent
5–9 0.70 (0.19–2.84) 0.65 (0.31–1.37)
10–14 1.00 (0.27–4.05) 2.25 (0.53–9.52) 1.00 (0.48–2.12)
15–24 1.99 (0.65–7.35) 4.55 (1.37–17.38) 1.77 (0.91–3.60)
25–55
 4.11 (1.37–14.99)
 9.13 (2.87–34.20)
 1.29 (0.55–2.94)
Sex 0.155 0.166 0.686
M Referent Referent Referent
F
 1.67 (0.84–3.51)
1.83 (0.80–4.55)
1.10 (0.70–1.72)
Preexisting conditions¶ 0.016 0.017 0.433
None/unknown Referent Referent Referent
Yes
 2.67 (1.13–5.67)
3.11 (1.12–7.48)
1.29 (0.64–2.34)
Occupation 0.935 0.025 0.177
Student Referent
Referent
Referent
At home# 1.11 (0.45–2.56) 3.81 (1.45–11.05) 1.64 (0.96–2.75)
Others**
 1.15 (0.50–2.54)
 1.70 (0.53–5.45)
 1.16 (0.66–2.01)
Level of education 0.917 0.191 0.164
Illiterate/no schooling Referent
Referent
Referent
Elementary 1.19 (0.52–2.89) 0.39 (0.12–1.06) 0.80 (0.45–1.42)
>Secondary
1.15 (0.48–2.85)
 0.61 (0.23–1.55)
 1.33 (0.78–2.32)
*Bold indicates statistical significance. IgG-S, IgG seroconverted; IgG-N, IgG negative; S, serosurvey.
†Paired survey intervals. S1–S2: July–December 2015; S2–S3: January 2016–May 2016; S3–S4: June 2016–March 2017.
‡p values based on χ2 test.
§Age groups 1–4 and 5–9 merged due to data scarcity in seroconverted participants.
¶Based on self-report by participants.
#Housewife, retired, unemployed.
**Business owners, employees, workers, etc.

Main Article

Page created: September 23, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external